open access

Vol 14, No 5 (2010)
Prace oryginalne
Published online: 2010-11-15
Get Citation

Evaluation of osteoprotegerin level and selected inflammatory markers in patients with essential hypertension

Lidia Kilińska, Paweł Bogdański, Ewa Miller-Kasprzak, Monika Szulińska, Danuta Pupek-Musialik, Anna Jabłecka, Paweł P. Jagodziński
Nadciśnienie tętnicze 2010;14(5):375-380.

open access

Vol 14, No 5 (2010)
Prace oryginalne
Published online: 2010-11-15

Abstract


Background Recent studies suggest that serum osteoprotegerin (OPG) levels increase in association with coronary artery calcification, coronary artery disease, stroke and future cardiovascular events. The aim of this study was to determine serum OPG levels and to investigate the relationship between OPG and selected inflammatory markers in hypertensive patients.
Material and methods Thirty patients with hypertension were studied. As a control 10 healthy volunteers were used. Physical examination was performed. Plasma OPG concentrations (OPG, enzyme-linked immunosorbent assay), high-sensitivity C-reactive protein (hs-CRP, turbidimetry method) and tumor necrosis factor α (TNF-α, radioimmunoassay) were determined.
Results The levels of plasma OPG, hsCRP and TNF-α significantly exceeded those observed in the control group (p < 0.05). Positive correlation between OPG and TNF-α (p < 0.05) was found.
Conclusions Hypertension is characterized by increased inflammatory process. The association of elevated OPG with TNF-α may provide a mechanistic link between coronary artery calcification, atherosclerosis progression and inflammation in this group of patients.
Arterial Hypertension 2010, vol. 14, no 5, pages 375-380.

Abstract


Background Recent studies suggest that serum osteoprotegerin (OPG) levels increase in association with coronary artery calcification, coronary artery disease, stroke and future cardiovascular events. The aim of this study was to determine serum OPG levels and to investigate the relationship between OPG and selected inflammatory markers in hypertensive patients.
Material and methods Thirty patients with hypertension were studied. As a control 10 healthy volunteers were used. Physical examination was performed. Plasma OPG concentrations (OPG, enzyme-linked immunosorbent assay), high-sensitivity C-reactive protein (hs-CRP, turbidimetry method) and tumor necrosis factor α (TNF-α, radioimmunoassay) were determined.
Results The levels of plasma OPG, hsCRP and TNF-α significantly exceeded those observed in the control group (p < 0.05). Positive correlation between OPG and TNF-α (p < 0.05) was found.
Conclusions Hypertension is characterized by increased inflammatory process. The association of elevated OPG with TNF-α may provide a mechanistic link between coronary artery calcification, atherosclerosis progression and inflammation in this group of patients.
Arterial Hypertension 2010, vol. 14, no 5, pages 375-380.
Get Citation

Keywords

arterial hypertension; osteoprotegerin; tumor necrosis factor; atherosclerosis

About this article
Title

Evaluation of osteoprotegerin level and selected inflammatory markers in patients with essential hypertension

Journal

Arterial Hypertension

Issue

Vol 14, No 5 (2010)

Pages

375-380

Published online

2010-11-15

Bibliographic record

Nadciśnienie tętnicze 2010;14(5):375-380.

Keywords

arterial hypertension
osteoprotegerin
tumor necrosis factor
atherosclerosis

Authors

Lidia Kilińska
Paweł Bogdański
Ewa Miller-Kasprzak
Monika Szulińska
Danuta Pupek-Musialik
Anna Jabłecka
Paweł P. Jagodziński

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl